Literature DB >> 11583677

Subclassification of preproliferative diabetic retinopathy and glycemic control: relationship between mean hemoglobin A1C value and development of proliferative diabetic retinopathy.

Y Sato1, Z Lee, Y Hayashi.   

Abstract

PURPOSE: We evaluated the relationship between long-term glycemic control and the proportion of patients developing proliferative diabetic retinopathy (PDR) among cases with mild type preproliferative diabetic retinopathy (PPDR).
METHODS: The relationship was evaluated between the mean hemoglobin A1C (HbA1C) value during a period of at least 2 years and the proportion of patients developing PDR among cases with mild type PPDR, based on our previously proposed subclassification.
RESULTS: During follow-up, 27% of the total PPDR cases developed PDR. The mean HbA1C value in those patients who had developed PDR was 9.4% and was significantly higher than the 7.6% in those who had not developed PDR. The proportion developing PDR was 48% of the cases with a mean HbA1C value of 8.6% or more. By comparison, the proportion developing PDR was 8% among those with a mean HbA1C value below 8.6%. The proportion developing PDR was estimated to approximately double with each 1% increase in the mean HbA1C value. The cumulative occurrence rates of PDR at 2, 5, and 10 years were estimated to be 5%, 28%, and 60% in cases with a mean HbA1C value of 8.6% or more, and 0%, 7%, and 14% in those with a mean HbA1C value below 8.6%, respectively.
CONCLUSION: Stricter systemic and ophthalmological control is indicated for cases with a mean HbA1C value exceeding 8.6%.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583677     DOI: 10.1016/s0021-5155(01)00380-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  3 in total

Review 1.  The unmet need for better risk stratification of non-proliferative diabetic retinopathy.

Authors:  S Sivaprasad; E Pearce
Journal:  Diabet Med       Date:  2018-12-07       Impact factor: 4.359

2.  Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study.

Authors:  Jing Wang; Peng-Fei Jiang; Min Liu; Ming-Rong Kou; Jia-Ying Lei; Xiao-Ting Yu; Ying Zhao; Hong Wang; Lin-Na Zhang
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

3.  Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study.

Authors:  Purificación Piñas García; Francisco Javier Hernández Martínez; Núria Aznárez López; Luis Castillón Torre; Mª Eugenia Tena Sempere
Journal:  Antioxidants (Basel)       Date:  2022-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.